Drugs / LTC004
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06277804 | Mar 2024 → Jul 2027 expected | — | Letolab | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05666635 | Dec 2022 → Dec 2024 | — | Letolab | Unknown | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06384248 | Apr 2024 → Dec 2025 | sarcoma | Letolab | Unknown | No outcome recorded |
| Phase 1/2 | NCT06384235 | Apr 2024 → Aug 2025 | colorectal cancer | Letolab | Unknown | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06490068 | Jun 2024 → Mar 2026 | neoplasm | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Unknown | No outcome recorded |
| Phase 2 | NCT06322563 | Apr 2024 → Mar 2025 | colorectal cancer | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT06255912 | Mar 2024 → Mar 2029 expected | malignant pancreatic neoplasm | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LTC004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06322563 ↗ |
| Route | Intravenous | “LTC004,90μg/kg,IV,Day 1,Q3W” NCT06322563 ↗ |